 |
|
 |
- May 16, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"The PROACTIVE Study: What are Its Implications for the Management of Diabetes in Canada?"Dr. Lawrence A. Leiter (biography)
English - 2005-09-14 - 35 minutes
|
 | (50 slides) |
Summary :
In this presentation Dr. Leiter reviews the major results of the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) study presented at the recent European Association for the Study of Diabetes (EASD) meeting in Athens.
Taking into account findings from the UK Prospective Diabetes Study (UKPDS), the 2003 Canadian Diabetes Association clinical practice guidelines recommend that in overweight type 2 diabetic patients with mild to moderate hyperglycemia, initial therapy should be a biguanide followed by an insulin sensitizer, insulin secretagogue, insulin or an alpha-glucosidase inhibitor (1). The glitazones improve insulin resistance and therefore a number of abnormalities contributing to the development of atherosclerosis, and it has been of interest to know the impact of glitazone treatment on vascular risk.
The PROactive study prospectively looked at the effects of pioglitazone treatment on total mortality and macrovascular morbidity in high-risk type 2 diabetic patients (2). Over 5000 patients received either pioglitazone or placebo in addition to existing therapy. Dr. Leiter presents the study design, and outcome and safety data as they were presented at the EASD meeting, and discusses how these results relate to the current Canadian treatment guidelines.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Current Canadian treatment guidelines for overweight type 2 diabetic patients with mild to moderate hyperglycemia
- Findings from the PROactive study presented at the 2005 EASD meeting
Bibliographic references :
1. CDA Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes. Dec,2003;27(Suppl 2): S39.
2. proactive-results.com The official PROactive results website
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
